The prevalence of clinically relevant herb-drug interactions between herbal products and anti-cancer therapy in older adults with cancer – A cross-sectional study

IF 1.8 Q3 PHARMACOLOGY & PHARMACY
Edwin J. Brokaar , Frederiek van den Bos , Johanneke E.A. Portielje , Loes E. Visser
{"title":"The prevalence of clinically relevant herb-drug interactions between herbal products and anti-cancer therapy in older adults with cancer – A cross-sectional study","authors":"Edwin J. Brokaar ,&nbsp;Frederiek van den Bos ,&nbsp;Johanneke E.A. Portielje ,&nbsp;Loes E. Visser","doi":"10.1016/j.rcsop.2025.100585","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The use of herbal supplements is highly prevalent amongst people with cancer and may lead to clinically relevant herb-drug interactions (HDIs) with their anti-cancer treatment. As the number of older adults with cancer increases, the numbers of older adults with cancer that are at risk of a HDI with anti-cancer treatment increases as well.</div></div><div><h3>Objective</h3><div>The goal of this study was to establish the prevalence of potentially relevant HDIs in older adults who undergo anti-cancer treatment. Also, the overall use of herbal products in this population and possible associations with patient characteristics were investigated.</div></div><div><h3>Method</h3><div>In this single center cross-sectional study patients aged ≥65 years were invited to participate if they underwent systemic anticancer treatment for a solid or hematological cancer. A questionnaire was developed to investigate the use of a selected set of frequently used herbs with known HDIs with regular medications. If a selected herb was used, the herb and oncological medication were assessed for potentially relevant HDIs. All potentially relevant HDIs were independently evaluated by two pharmacists on clinical relevance.</div></div><div><h3>Results</h3><div>A total of 202 patients were included in the analysis. The mean age was 74 years and 54 % was male. The prevalence of potentially relevant HDIs was 4 % and overall herb use was 12 %. Thirteen potentially relevant HDIs were identified, of which 6 were judged to be clinically relevant. The clinically relevant HDIs concerned red yeast rice, red coneflower, turmeric, and cannabis. None of the patient characteristics were associated with overall herb use.</div></div><div><h3>Conclusion</h3><div>Potentially relevant HDIs between herbal supplements and oncological treatment occur in 4 % of older adults with cancer and half of these are clinically relevant. Healthcare providers should question patients with cancer on the use of herbal supplements and monitor for relevant HDI with the treatment given.</div></div>","PeriodicalId":73003,"journal":{"name":"Exploratory research in clinical and social pharmacy","volume":"18 ","pages":"Article 100585"},"PeriodicalIF":1.8000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploratory research in clinical and social pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667276625000265","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The use of herbal supplements is highly prevalent amongst people with cancer and may lead to clinically relevant herb-drug interactions (HDIs) with their anti-cancer treatment. As the number of older adults with cancer increases, the numbers of older adults with cancer that are at risk of a HDI with anti-cancer treatment increases as well.

Objective

The goal of this study was to establish the prevalence of potentially relevant HDIs in older adults who undergo anti-cancer treatment. Also, the overall use of herbal products in this population and possible associations with patient characteristics were investigated.

Method

In this single center cross-sectional study patients aged ≥65 years were invited to participate if they underwent systemic anticancer treatment for a solid or hematological cancer. A questionnaire was developed to investigate the use of a selected set of frequently used herbs with known HDIs with regular medications. If a selected herb was used, the herb and oncological medication were assessed for potentially relevant HDIs. All potentially relevant HDIs were independently evaluated by two pharmacists on clinical relevance.

Results

A total of 202 patients were included in the analysis. The mean age was 74 years and 54 % was male. The prevalence of potentially relevant HDIs was 4 % and overall herb use was 12 %. Thirteen potentially relevant HDIs were identified, of which 6 were judged to be clinically relevant. The clinically relevant HDIs concerned red yeast rice, red coneflower, turmeric, and cannabis. None of the patient characteristics were associated with overall herb use.

Conclusion

Potentially relevant HDIs between herbal supplements and oncological treatment occur in 4 % of older adults with cancer and half of these are clinically relevant. Healthcare providers should question patients with cancer on the use of herbal supplements and monitor for relevant HDI with the treatment given.
中草药产品与老年癌症患者抗癌治疗之间临床相关中草药相互作用的流行-一项横断面研究
在癌症患者中,草药补充剂的使用非常普遍,并且可能导致临床相关的草药药物相互作用(hdi)与他们的抗癌治疗。随着患癌症的老年人数量的增加,接受抗癌治疗的患HDI风险的老年人数量也在增加。本研究的目的是确定接受抗癌治疗的老年人中潜在相关hdi的患病率。此外,还调查了该人群中草药产品的总体使用情况及其与患者特征的可能关联。方法在这项单中心横断面研究中,年龄≥65岁的患者被邀请参加,如果他们因实体癌或血液病接受了全身抗癌治疗。制定了一份调查问卷,以调查一组已知hdi的常用草药与常规药物的使用情况。如果使用选定的草药,则评估草药和肿瘤药物的潜在相关hdi。所有可能相关的hdi由两名药剂师独立评估临床相关性。结果共纳入202例患者。平均年龄为74岁,男性占54%。潜在相关hdi患病率为4%,总体草药使用率为12%。确定了13个可能相关的hdi,其中6个被判定为临床相关。临床相关的hdi涉及红曲米、红圆锥花、姜黄和大麻。没有患者的特征与整体草药使用相关。结论:在4%的老年癌症患者中,草药补充剂和肿瘤治疗之间存在潜在的相关hdi,其中一半具有临床相关性。医疗保健提供者应询问癌症患者使用草药补充剂的情况,并监测所给予治疗的相关HDI。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
0
审稿时长
103 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信